Inventor profile of:

Don J. Diamond

City:

Glendora, California

Country:

United States

Published Applications:

39

Last publication date:

2025-10-09

Top Assignees for applications by Don J. Diamond

The entities that hold a legal rights for patent applications filed by inventor Diamond Don J.:

Recent patent applications by Diamond Don J.

Don J. Diamond from Glendora, US has applied for patents for these inventions. The list has both pending applications and granted patents:

#1 | 2025-10-09
US20250313858A1
Chemistry; metallurgy

SYNTHETIC MODIFIED VACCINIA ANKARA (SMVA) BASED CORONAVIRUS VACCINES

#2 | 2025-07-03
US20250215456A1
Chemistry; metallurgy

POXVIRUS-BASED VECTORS PRODUCED BY NATURAL OR SYNTHETIC DNA AND USES THEREOF

#3 | 2024-06-27
US20240207393A1
Human necessities

Use of endogenous viral vaccine in chimeric antigen receptor T cell therapy

#4 | 2024-03-14
US20240082403A1
Human necessities

Chimeric Antigen Receptors against Human Cytomegalovirus

#5 | 2023-12-14
US20230398209A1
Human necessities

MVA vaccine for delivery of a UL128 complex and preventing CMV infection

#6 | 2023-10-12
US20230323389A1
Chemistry; metallurgy

SYNTHETIC MODIFIED VACCINIA ANKARA (SMVA) BASED CORONAVIRUS VACCINES

#7 | 2023-09-21
US20230293675A1
Human necessities

GENETICALLY STABLE RECOMBINANT MODIFIED VACCINIA ANKARA (RMVA) VACCINES AND METHODS OF PREPARATION THEREOF

#8 | 2023-07-27
US20230233666A1
Human necessities

SYNTHETIC MODIFIED VACCINIA ANKARA (sMVA) BASED CORONAVIRUS VACCINES

#9 | 2023-05-04
US20230140549A1
Human necessities

Expression system for expressing herpesvirus glycoprotein complexes

#10 | 2023-03-30
US20230097513A1
Chemistry; metallurgy

POXVIRUS-BASED VECTORS PRODUCED BY NATURAL OR SYNTHETIC DNA AND USES THEREOF

#11 | 2022-08-04
US20220241432A1
Human necessities

ANTICANCER COMBINATIONS

#12 | 2022-06-23
US20220193149A1
Human necessities

COMPOSITIONS AND METHODS FOR TARGETING TUMOR-ASSOCIATED EXTRACELLULAR MATRIX COMPONENTS TO IMPROVE DRUG DELIVERY

#13 | 2022-03-03
US20220062410A1
Human necessities

Use of endogenous viral vaccine in chimeric antigen receptor T cell therapy

#14 | 2021-06-17
US20210177962A1
Human necessities

MVA vaccine for delivery of a UL128 complex and preventing CMV infection

#15 | 2021-03-04
US20210062221A1
Chemistry; metallurgy

Genetically modified recombinant vaccinia ankara (RMVA) vaccines of improved stability and methods of preparation thereof

#16 | 2021-03-04
US20210060155A1
Human necessities

MVA VECTORS FOR EXPRESSING MULTIPLE CYTOMEGALOVIRUS (CMV) ANTIGENS AND USE THEREOF

#17 | 2020-08-06
US20200246455A1
Human necessities

Synthetic conjugate of CpG DNA and T-help/CTL peptide

#18 | 2020-05-21
US20200157549A1
Chemistry; metallurgy

Tumor associated vaccines and compositions for disrupting tumor-derived immunosuppression for use in combination cancer immunotherapy

#19 | 2020-05-21
US20200157191A1
Chemistry; metallurgy

MVA-gH/gL-PC vaccine derived antibodies neutralizing human cytomegalovirus infectivity and methods thereof

#20 | 2020-05-21
US20200155670A1
Human necessities

Expression system for expressing herpesvirus glycoprotein complexes

#21 | 2020-03-05
US20200069791A1
Human necessities

MVA vaccine for delivery of a UL128 complex and preventing CMV infection

#22 | 2020-02-20
US20200054736A1
Human necessities

Use of endogenous viral vaccine in chimeric antigen receptor T cell therapy

#23 | 2020-02-13
US20200046785A1
Human necessities

P53-targeting vaccines and pd-1 pathway inhibitors and methods of use thereof

#24 | 2019-05-23
US20190153452A1
Chemistry; metallurgy

Tumor associated vaccines and compositions for disrupting tumor-derived immunosuppression for use in combination cancer immunotherapy

#25 | 2018-10-25
US20180303930A1
Human necessities

MVA vaccine for delivery of a UL128 complex and preventing CMV infection

#26 | 2018-08-30
US20180243409A1
Human necessities

Synthetic conjugate of CpG DNA and T-help/CTL peptide

#27 | 2018-08-16
US20180230200A1
Chemistry; metallurgy

MVA-gh/gL-PC vaccine derived antibodies neutralizing human cytomegalovirus infectivity and methods thereof

#28 | 2017-08-31
US20170246273A1
Human necessities

RECOMBINANT LISTERIA STRAIN EXPRESSING HETEROLOGOUS ANTIGEN FUSION PROTEINS AND METHODS OF USE THEREOF

#29 | 2017-03-23
US20170081671A1
Chemistry; metallurgy

Tumor associated vaccines and compositions for disrupting tumor-derived immunosuppression for use in combination cancer immunotherapy

#30 | 2016-06-30
US20160184456A1
Human necessities

Anticancer combinations

#31 | 2016-01-07
US20160000906A1
Human necessities

Synthetic conjugate of CpG DNA and T-help/CTL peptide

#32 | 2015-08-06
US20150216965A1
Human necessities

MVA vaccine for delivery of a UL128 complex and preventing CMV infection

#33 | 2014-07-03
US20140186401A1
Chemistry; metallurgy

Tumor associated vaccines and compositions for disrupting tumor-derived immunosuppression for use in combination cancer immunotherapy

#34 | 2007-09-27
US20070224195A1
Chemistry; metallurgy

Modified vaccinia ankara expressing P53 in cancer immunotherapy

#35 | 2007-08-14
US10746558
-

Modified vaccinia Ankara expressing p53 in cancer immunotherapy

#36 | 2005-10-04
US10643888
-

CTL epitope analogs

#37 | 2005-07-21
US20050158336A1
Human necessities

Synthetic conjugate of CpG DNA and T-help/CTL peptide

#38 | 2005-01-27
US20050019754A1
Chemistry; metallurgy

Diagnostic reagents for human cytomegalovirus and methods of use

#39 | 2005-01-18
US10697055
-

Immuno-reactive peptide CTL epitopes of human cytomegalovirus

InventorID:

823503 ⎘